An antibiotics biotech begins wind-down, lays off nearly all workers
An antibiotics biotech is about to throw in the towel, dealing another blow to a sparse R&D field and raising red flags in the light of antimicrobial resistance.
Nabriva Therapeutics, which has been soul searching for the past two months with an advisor, is laying off nearly all its employees, returning the promotion and distribution rights of an antibacterial to Merck, canceling a loan agreement and making other moves to “adequately fund an orderly wind down of the Company’s operations.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.